logo-loader
viewAtossa Genetics Inc

Atossa Genetics kicks off Phase 2 study of topical Endoxifen to reduce breast density

Studies show that a reduction in breast density reduces the risk of developing breast cancer

Woman getting a breast exam
Endoxifen is an active metabolite of tamoxifen, the FDA-approved breast cancer drug

Atossa Genetics Inc (NASDAQ:ATOS), a clinical-stage pharmaceutical group, has opened its Phase 2 study of its topical drug Endoxifen, which is used to reduce the density of breasts.

Studies show that a reduction in breast density reduces the risk of developing breast cancer in women and could improve the accuracy of mammography in finding cancer.

The primary endpoint of this Phase 2 study is to determine if topical Endoxifen results in a change in mammographic breast density (MBD), which will be measured at three months and at six months after entering the study. The secondary endpoints in the study, which will analyze ninety participants, are safety and tolerability.

“The objective of the study is to determine if MBD is reduced, and if so, the results will drive sample size calculations for a future Phase III study,” according to Atossa.

The Phase 2 study is being conducted at Stockholm South General Hospital in Sweden and is being led by Dr Per Hall, head of the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet.

Last week, the company completed dosing and clinical visits in a Phase 1 study of its proprietary topical endoxifen for treatment of gynecomastia, or male breast enlargement, in men.

Maxim has bullish take

Jason McCarthy, a research analyst with Maxim Group, is bullish on Endoxifen and is keeping a Buy rating and a $10 price target on Atossa’s stock.

“Catalysts lay ahead as data emerges from ongoing and upcoming studies, which if positive should drive a higher valuation,” he wrote. “Both the topical and oral formulations of endoxifen continue to advance and management is executing on its clinical strategy.”

Atossa also plans to start a Phase 2 study to assess the worth of Endoxifen when taken orally by newly-diagnosed breast cancer patients.

Endoxifen is an active metabolite of tamoxifen. Tamoxifen is an FDA-approved drug to prevent new breast cancer as well as recurrent breast cancer in breast cancer patients.

Atossa shares were recently up 1.6% to US$2.38.

Quick facts: Atossa Genetics Inc

Price: 1.41 USD

NASDAQ:ATOS
Market: NASDAQ
Market Cap: $12.83 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Helix Technologies following up strong 2019 with success in 2020

Helix Technologies (OTCQB: HLIX) President of Data Services Garvis Toler joined Steve Darling from Proactive Vancouver to discuss the company releasing their 2019 financial numbers which were very strong and also what milestones they hit to close the year.  Toler also told Proactive...

2 days, 19 hours ago

2 min read